JP2015505959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505959A5 JP2015505959A5 JP2014545002A JP2014545002A JP2015505959A5 JP 2015505959 A5 JP2015505959 A5 JP 2015505959A5 JP 2014545002 A JP2014545002 A JP 2014545002A JP 2014545002 A JP2014545002 A JP 2014545002A JP 2015505959 A5 JP2015505959 A5 JP 2015505959A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cancer
- inhibitor
- group
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161567085P | 2011-12-05 | 2011-12-05 | |
| US61/567,085 | 2011-12-05 | ||
| US201261728748P | 2012-11-20 | 2012-11-20 | |
| US61/728,748 | 2012-11-20 | ||
| PCT/US2012/068005 WO2013086031A1 (en) | 2011-12-05 | 2012-12-05 | Method of therapy selection for patients with cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017191195A Division JP2018054614A (ja) | 2011-12-05 | 2017-09-29 | 癌を有する患者に治療を選択する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505959A JP2015505959A (ja) | 2015-02-26 |
| JP2015505959A5 true JP2015505959A5 (enExample) | 2016-01-28 |
Family
ID=48574842
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014545002A Pending JP2015505959A (ja) | 2011-12-05 | 2012-12-05 | 癌を有する患者に治療を選択する方法 |
| JP2017191195A Pending JP2018054614A (ja) | 2011-12-05 | 2017-09-29 | 癌を有する患者に治療を選択する方法 |
| JP2019182229A Pending JP2020024210A (ja) | 2011-12-05 | 2019-10-02 | 癌を有する患者に治療を選択する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017191195A Pending JP2018054614A (ja) | 2011-12-05 | 2017-09-29 | 癌を有する患者に治療を選択する方法 |
| JP2019182229A Pending JP2020024210A (ja) | 2011-12-05 | 2019-10-02 | 癌を有する患者に治療を選択する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140273006A1 (enExample) |
| EP (1) | EP2788752B1 (enExample) |
| JP (3) | JP2015505959A (enExample) |
| WO (1) | WO2013086031A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1211218A1 (en) * | 2012-12-07 | 2016-05-20 | 综合医院公司 | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
| AU2014239903A1 (en) * | 2013-03-14 | 2015-09-17 | Genentech, Inc. | Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| EP3107578A2 (en) * | 2014-02-20 | 2016-12-28 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| CA2955141A1 (en) * | 2014-07-23 | 2016-01-28 | Ontario Institute For Cancer Research | Systems, devices and methods for constructing and using a biomarker |
| JP6782698B2 (ja) * | 2014-12-12 | 2020-11-11 | セルキュイティー インコーポレイテッド | がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法 |
| EP3286565B1 (en) * | 2015-04-21 | 2025-01-15 | Genentech, Inc. | Compositions and methods for prostate cancer analysis |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| JP6698712B2 (ja) * | 2015-06-29 | 2020-05-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｔａｓｅｌｉｓｉｂを用いた治療方法 |
| EP3363911B1 (en) * | 2015-10-14 | 2024-09-25 | Nitto Boseki Co., Ltd. | Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used |
| JP2019519772A (ja) * | 2016-05-31 | 2019-07-11 | ネステク ソシエテ アノニム | Ｈｅｒ２及びｈｅｒ３の経路サブタイピングに基づく乳癌患者の薬物療法の選択方法 |
| US20180117029A1 (en) * | 2016-11-03 | 2018-05-03 | Beth Israel Deaconess Medical Center, Inc. | Targeting Metabolic Vulnerability in Triple-Negative Breast Cancer |
| SG11201909218RA (en) | 2017-04-03 | 2019-11-28 | Hoffmann La Roche | Antibodies binding to steap-1 |
| CN113683700B (zh) * | 2017-06-22 | 2023-05-02 | 北海康成（北京）医药科技有限公司 | 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒 |
| WO2020081956A1 (en) * | 2018-10-18 | 2020-04-23 | Medimmune, Llc | Methods for determining treatment for cancer patients |
| KR102267593B1 (ko) * | 2018-10-19 | 2021-06-21 | 주식회사 프로티나 | Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법 |
| CN111888487B (zh) * | 2020-09-04 | 2022-05-17 | 山西医科大学 | 肿瘤靶向型光声成像引导多阶段治疗纳米探针及制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
| US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
| CA2170873A1 (en) | 1993-09-03 | 1995-03-09 | Dariush Davalian | Fluorescent oxygen channeling immunoassays |
| US20090142272A1 (en) * | 2004-06-21 | 2009-06-04 | Exelixis, Inc. | Pfks as modifiers of the igfr pathway and methods of use |
| WO2008036802A2 (en) | 2006-09-21 | 2008-03-27 | Prometheus Laboratories Inc. | Antibody-based arrays for detecting multiple signal transducers in rare circulating cells |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| BRPI0813583A2 (pt) * | 2007-07-13 | 2014-12-30 | Prometheus Lab Inc | Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo |
| EP2235536A4 (en) * | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
| NZ600339A (en) * | 2008-02-25 | 2013-12-20 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
| US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
| EP2430443B1 (en) | 2009-05-14 | 2018-06-27 | Pierian Holdings, Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| AU2010273319B2 (en) | 2009-07-15 | 2015-01-22 | Nestec S.A. | Drug selection for gastric cancer therapy using antibody-based arrays |
| MX337666B (es) | 2009-10-20 | 2016-03-14 | Nestec Sa | Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas. |
| RU2558931C2 (ru) * | 2010-01-12 | 2015-08-10 | Нестек С.А. | Способы предсказания ответа трижды негативного рака молочной железы на терапию |
| US20110217701A1 (en) * | 2010-03-03 | 2011-09-08 | Carter Scott L | Prognostic Marker for Endometrial Carcinoma |
| JP2014503821A (ja) * | 2010-12-23 | 2014-02-13 | ネステク ソシエテ アノニム | 抗体ベースのアレイを用いる悪性がんの療法のための薬剤選択 |
| EP2681552A2 (en) * | 2011-03-02 | 2014-01-08 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
-
2012
- 2012-12-05 EP EP12855900.2A patent/EP2788752B1/en active Active
- 2012-12-05 WO PCT/US2012/068005 patent/WO2013086031A1/en not_active Ceased
- 2012-12-05 JP JP2014545002A patent/JP2015505959A/ja active Pending
-
2014
- 2014-06-03 US US14/294,449 patent/US20140273006A1/en not_active Abandoned
-
2017
- 2017-09-29 JP JP2017191195A patent/JP2018054614A/ja active Pending
-
2019
- 2019-10-02 JP JP2019182229A patent/JP2020024210A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cohen | Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC) | |
| Qi et al. | Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer | |
| EA201200025A1 (ru) | Биомаркеры и способы определения эффективности анти-egfr антител для лечения злокачественного новообразования | |
| RU2017125053A (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
| Skoura et al. | Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non–small-cell lung cancer | |
| RU2012109556A (ru) | Биологические маркеры для мониторирования ответа пациента на антагонисты vegf | |
| Machiels et al. | Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) | |
| US20140273006A1 (en) | Method of therapy selection for patients with cancer | |
| Bencsikova et al. | Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view | |
| Peng et al. | Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a propensity score matching analysis | |
| JP2014533960A5 (enExample) | ||
| RU2013148768A (ru) | Способы предсказания и улучшения выживаемости пациентов с раком желудка | |
| Gardini et al. | Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group | |
| Milella et al. | EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy | |
| Hatch et al. | Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) | |
| Dziadziuszko et al. | Epidermal growth factor receptor (EGFR) inhibitors and derived treatments | |
| Shaya et al. | Prognostic significance of pancreatic metastases in patients with advanced renal cell carcinoma treated with systemic therapy | |
| JP2017529852A5 (enExample) | ||
| Krause et al. | Effective control of recalcitrant pruritus by bevacizumab: a possible role for vascular endothelial growth factor in chronic itch? | |
| Sudhindra et al. | Biomarkers, prediction, and prognosis in non–small-cell lung cancer: a platform for personalized treatment | |
| Baselga et al. | Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788 | |
| Song et al. | Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib | |
| US10640830B2 (en) | Drug selection for non-small cell lung cancer therapy | |
| Moldvay | Personalized treatment in non-small cell lung cancer: from diagnostics to therapy | |
| JP2015527341A5 (enExample) |